SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-047493
Filing Date
2023-06-08
Accepted
2023-06-08 16:30:24
Documents
13
Period of Report
2023-06-04
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea180017-8k_biondvax.htm   iXBRL 8-K 29036
  Complete submission text file 0001213900-23-047493.txt   247007

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bvxv-20230604.xsd EX-101.SCH 3745
3 XBRL DEFINITION FILE bvxv-20230604_def.xml EX-101.DEF 26678
4 XBRL LABEL FILE bvxv-20230604_lab.xml EX-101.LAB 36809
5 XBRL PRESENTATION FILE bvxv-20230604_pre.xml EX-101.PRE 25302
7 EXTRACTED XBRL INSTANCE DOCUMENT ea180017-8k_biondvax_htm.xml XML 5494
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37353 | Film No.: 231002318
SIC: 2836 Biological Products, (No Diagnostic Substances)